Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Acta gastroenterol. latinoam ; 32(1): 20-17, maiy 2002. tab
Article Dans Espagnol | LILACS | ID: lil-316193

Résumé

Dexketoprofene (De) NSAID was studied as a selective COX-1 inhibitor in comparison with Ketorolac (Ke), a mainly COX-1 inhibitor. De and Ke were administered to different groups of animals in a dose-dependent manner, i.e., 3-15 and 25 mgs/kg. The gastrointestinal mucosa damage was macroscopically and microscopically quantified at 24 hs, as well as leukocyte infiltration (LI) and neosinophilia. Similarly, Indomethacin (Indo) damage (COX-1-COX-2), with 25 mgs/kg. Dose was compared. On the other hand, De and Ke at inhibitory selective COX-1 dose (3 mg/kg) plus Celecoxib, selective COX-2 inhibitor, yielding no gastrointestinal damage, with decreased LI and without neutrophilia, the same as Ke (n.s.). Similarly De at higher dose (2.5 mgs/kg), produced minimal gastrointestinal lesions, showing a preferential COX-1 inhibitor behavior. Ke and Indo produced important gastrointestinal necrotic and erosive lesions with remarkable LI and neutrophilia (p < 0.001). On the other hand, COX-1 De dose plus Celecoxib produced evident gastrointestinal lesions, increased LI and neutrophilia, the same as Indo, pointing out that the gastrointestinal damage is due to COX-1 and COX-2 inhibition


Sujets)
Humains , Animaux , Rats , Inhibiteurs des cyclooxygénases , Muqueuse intestinale , Kétoprofène , Trométhamine , Analyse de variance , Muqueuse gastrique , Muqueuse intestinale , Kétorolac , Rat Wistar , Sulfonamides
2.
Medicina (B.Aires) ; 60(2): 221-4, 2000. ilus, tab
Article Dans Espagnol | LILACS | ID: lil-262215

Résumé

En diferentes grupos de ratas Wistar (n = 15 en c/grupo), se estudiaron las dosis ulcerogénicas AINES COX-1 como Indometacina vs Celecoxib (inhibidor selectivo COX-2), en la producción de úlceras antrales gástricas y necrosis de la mucosa del intestino delgado y colon. Se encontró que Celecoxib, dado en forma oral o subcutánea cada 12 hs durante 5 días, no provocó lesiones en mucosa gastrointestinal, en cambio, dado el Celecoxib después de la Indometacina, agravé las úlceras antrales gástricas y dio necrosis masiva tanto del intestino delgado y del colon y óbito de todas las ratas. Se concluyó que Celecoxib no provocó lesiones gastrointestinales en mucosa sana; en contraste, se amplificaron las lesiones preexistentes gastrointestinales inducidas por Indometacina.


Sujets)
Animaux , Rats , Femelle , Anti-inflammatoires non stéroïdiens/effets indésirables , Inhibiteurs des cyclooxygénases/toxicité , Système digestif/effets des médicaments et des substances chimiques , Indométacine/effets indésirables , Ulcère gastrique/induit chimiquement , Sulfonamides/toxicité , Inhibiteurs des cyclooxygénases/administration et posologie , Nécrose , Antre pylorique/traumatismes , Rat Wistar , Ulcère gastrique/anatomopathologie , Sulfonamides/administration et posologie
SÉLECTION CITATIONS
Détails de la recherche